Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.71% |
| Mar 31, 2026 | -62.21% |
| Dec 31, 2025 | 41.50% |
| Sep 30, 2025 | 17.92% |
| Jun 30, 2025 | 16.34% |
| Mar 31, 2025 | 14.88% |
| Dec 31, 2024 | -52.80% |
| Sep 30, 2024 | 17.95% |
| Jun 30, 2024 | 19.46% |
| Mar 31, 2024 | -2.38% |
| Dec 31, 2023 | -19.57% |
| Sep 30, 2023 | -3.64% |
| Jun 30, 2023 | -29.83% |
| Mar 31, 2023 | -16.67% |
| Dec 31, 2022 | -29.54% |
| Sep 30, 2022 | -22.74% |
| Jun 30, 2022 | -27.28% |
| Mar 31, 2022 | -42.17% |
| Dec 31, 2021 | -10.44% |
| Sep 30, 2021 | -40.53% |